Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Rivastigmine
Drug ID BADD_D01955
Description Rivastigmine is a parasympathomimetic or cholinergic agent for the treatment of mild to moderate dementia of the Alzheimer's type. Rivastigmine is a cholinesterase inhibitor that inhibits both butyrylcholinesterase and acetylcholinesterase.
Indications and Usage For the treatment of mild to moderate dementia associated with Parkinson's disease or of the Alzheimer's type.
Marketing Status Prescription; Discontinued
ATC Code N06DA03
DrugBank ID DB00989
KEGG ID D03822
MeSH ID D000068836
PubChem ID 77991
TTD Drug ID D0WY5Q
NDC Product Code 0378-9071; 51956-0001; 51956-0003; 70710-1198; 65162-826; 49706-1825; 51956-0002; 0078-0502; 72855-100; 0378-9070; 50379-0014; 65015-819; 46708-835; 51991-899; 0078-0503; 63629-8846; 65862-982; 65162-825; 72855-101; 63629-8807; 63629-2065; 65162-749; 51991-898; 0378-9072; 64552-4021; 0781-7313; 72855-102; 16714-117; 16714-116; 51991-897; 0781-7309; 70710-1196; 12651-118; 63629-2066; 0078-0501; 16714-115; 0781-7304; 65372-1153; 82245-0107; 63629-2064; 70710-1197
Synonyms Rivastigmine | (S)-N-Ethyl-3-((1-dimethyl-amino)ethyl)-N-methylphenylcarbamate | RivastigmineTartrate | Rivastigmine Hydrogen Tartrate | Hydrogen Tartrate, Rivastigmine | Tartrate, Rivastigmine Hydrogen | Exelon | ENA 713 | 713, ENA | SDZ ENA 713 | 713, SDZ ENA | ENA 713, SDZ | ENA-713 | ENA713
Chemical Information
Molecular Formula C14H22N2O2
CAS Registry Number 123441-03-2
SMILES CCN(C)C(=O)OC1=CC=CC(=C1)C(C)N(C)C
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
AstheniaCholinesteraseP06276T9979911475943; 9880090; 16437532; 10090427
DiarrhoeaCholinesteraseP06276T9979911475943; 9880090; 16437532; 10090427
DizzinessCholinesteraseP06276T9979911475943; 9880090; 16437532; 10090427
VomitingCholinesteraseP06276T9979911475943; 9880090; 16437532; 10090427
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal discomfort07.01.06.0010.002484%Not Available
Abdominal distension07.01.04.0010.002484%
Abdominal pain07.01.05.0020.004968%
Abdominal pain upper07.01.05.003--
Abnormal dreams19.02.03.001; 17.15.02.0010.002484%Not Available
Aggression19.05.01.0010.002484%Not Available
Agitation19.06.02.001; 17.02.05.0120.004968%
Anxiety19.06.02.002--
Application site erythema23.03.06.005; 12.07.01.001; 08.02.01.001--Not Available
Application site irritation12.07.01.003; 08.02.01.003--Not Available
Application site pruritus23.03.12.004; 12.07.01.005; 08.02.01.005--Not Available
Asthenia08.01.01.0010.003726%Not Available
Atrial fibrillation02.03.03.002--
Atrioventricular block02.03.01.0020.003726%Not Available
Blister23.03.01.001; 12.01.06.002--Not Available
Bradycardia02.03.02.0020.011178%Not Available
Bradykinesia17.01.02.0040.004968%Not Available
Cardiac arrest02.03.04.0010.001620%
Cholinergic syndrome17.05.01.0020.003726%Not Available
Circulatory collapse24.06.02.0010.000972%Not Available
Cogwheel rigidity15.05.04.006; 17.01.05.001--Not Available
Confusional state19.13.01.001; 17.02.03.0050.011178%
Constipation07.02.02.0010.003726%
Death08.04.01.001--
Dehydration14.05.05.0010.002484%
Delirium19.13.02.0010.006210%
Dementia19.20.02.001; 17.03.01.0010.002484%Not Available
Dementia Alzheimer's type19.20.03.001; 17.03.06.0010.007452%Not Available
Depressed level of consciousness17.02.04.0020.002484%
Depression19.15.01.0010.003726%
The 1th Page    1 2 3 4    Next   Last    Total 4 Pages